Lindhe Xtend is now entering the next phase with an international expansion. In order to support the company, a new board has been appointed. The new board strengthens the competence of the company and provides expertise within internationalization, commercialization and clinical expertise:
Tommy Hedberg, Chairman of the board
Tommy Hedberg has a long experience from international business and has held positions as MD at Atos Medical, VP of Marketing & Sales at both Atos and Medscand, and as Product Manager at Leo Pharma. With his international expertise, solid experience and board experience, Tommy will be a great asset for the company.
Peter Gerhardsson, Member of the board
Peter Gerhardsson has over 30 years of experience from the pharmaceutical and med tech industry. His focus on sales and marketing, primarily within the segment of diabetes, contributes a valuable and broad international network. Peter holds the position as VP at Dexcom and has previously been responsible for business development at Novo Nordisk and Medtronic.
Henrik Malchau, Member of the board
Henrik Malchau is a Professor at Harvard Medical School at Massachusetts General Hospital and Chief Physician at the Orthopedic Department at Sahlgrenska University Hospital in Göteborg. With his long experience both of clinical work and research, Henrik will contribute with a strong international network and clinical expertise within the orthopedic field.
Anders Rosengren, Member of the board
Anders Rosengren has 20 years of experience in business development of medical devices in both start-ups and mid-sized companies. Anders contributes with a solid technical expertise, broad network as well as commercial and international experience.
Christoffer Lindhe, Member of the board, Product Development Director and founder of the Company
Christoffer Lindhe plays an important role in the board as the Founder and Majority owner. With his contacts, innovations and inspirational approach, he constributes both practially and strategically to the development of the Company.
